We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Quidel (QDEL) to Report Q1 Earnings: What's in the Offing?
Read MoreHide Full Article
Quidel Corporation (QDEL - Free Report) is expected to report first-quarter fiscal 2021 results on May 6, 2021.
The company delivered an earnings surprise of 9.6% in the last reported quarter. Further, its bottom line beat estimates in each of the trailing four quarters, the average being 30.9%.
Q1 Estimates
The Zacks Consensus Estimate for total revenues of $375.2 million implies growth of 114.9% from the prior-year quarter’s reported figure. Also, the consensus mark for earnings per share (EPS) is pegged at $4.87, indicating significant growth from the prior-year quarter’s reported figure.
Factors at Play
In the last reported quarter, Quidel’s Molecular Diagnostic Solutions delivered robust results. This momentum is likely to have continued in the to-be reported quarter as well. Further, higher sales of COVID-19 products are expected to have boosted growth in the to-be-reported quarter.
The company is likely to have witnessed an uptick in rapid immunoassay revenues in the fiscal first quarter on higher sales derived from the Sofia platform. Progress of this platform is expected to have been aided by an increase in Sofia SARS Antigen and Sofia Combo ABC product sales.
However, Quidel witnessed a decline in its specialized diagnostic solutions revenues in the last reported quarter. This downside was due to weak respiratory products in the company’s Cell Culture business, a trend that most likely continued in the fiscal first quarter too.
Also, Quidel witnessed softness in its overall Influenza revenues in the fourth quarter of fiscal 2020 due to a very low prevalence of Influenza in the period, a trend that most likely persisted in the first quarter of fiscal 2021 as well.
Nonetheless, overall molecular growth of the Lyra product category is expected to have contributed to the to-be-reported quarter’s top line, possibly led by an uptick in Solana SARS revenues.
In the to-be reported quarter, the company’s Cardiometabolic Immunoassay business is expected to have been driven by strength in the Triage business and the Beckman BNP business.
Advancement of the COVID-diagnostic product pipeline, especially with the Sofia Serology assay, is expected to have boosted the company’s performance in the fiscal first quarter. The FDA EUA approvals to market Solana SARS and QuickVue SARS Antigen is also expected to have driven growth in the to-be reported quarter.
Quidel has been evolving within its R&D and instrument systems development teams for a while now. This, in turn, is expected to reflect on its results for the fiscal first quarter. Moreover, solid momentum of the Savanna cross-functional product development team might have enhanced the company’s to-be-reported quarter’s performance.
In recent times, Sofia Q, formerly named Sniffles, which is the company’s next-generation Sofia platform, is steadily gaining traction. This is also likely to have bumped up the top line in the to-be-reported quarter.
Additionally, the company is expected to have consistently benefited from newer products like Sofia Lyme, TriageTrue, High Sense, Troponin assay, Triage PLGF and the new Sofia GI suite in the quarter as well.
What Our Quantitative Model Suggests
Our proven model does not predict an earnings beat for Quidel this time around. The combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the chances of an earnings beat. But that is not the case here as you will see.
Earnings ESP: Quidel has an Earnings ESP of -2.47%. You can uncover the best stocks to buy or sell before they're reported with our Earnings ESP Filter.
Zacks Rank: Quidel carries a Zacks Rank #5 (Strong Sell).
Zacks Rank and Key Picks
Here are some medical stocks worth considering as these have the right combination of elements to beat on earnings this reporting cycle.
DENTSPLY SIRONA (XRAY - Free Report) has an Earnings ESP of +11.36% and is a Zacks #2 Ranked stock, presently.
Cerner Corporation has an Earnings ESP of +0.37% and a Zacks Rank of 3 at present.
More Stock News: This Is Bigger than the iPhone!
It could become the mother of all technological revolutions. Apple sold a mere 1 billion iPhones in 10 years but a new breakthrough is expected to generate more than 77 billion devices by 2025, creating a $1.3 trillion market.
Zacks has just released a Special Report that spotlights this fast-emerging phenomenon and 4 tickers for taking advantage of it. If you don't buy now, you may kick yourself in 2022.
Image: Bigstock
Quidel (QDEL) to Report Q1 Earnings: What's in the Offing?
Quidel Corporation (QDEL - Free Report) is expected to report first-quarter fiscal 2021 results on May 6, 2021.
The company delivered an earnings surprise of 9.6% in the last reported quarter. Further, its bottom line beat estimates in each of the trailing four quarters, the average being 30.9%.
Q1 Estimates
The Zacks Consensus Estimate for total revenues of $375.2 million implies growth of 114.9% from the prior-year quarter’s reported figure. Also, the consensus mark for earnings per share (EPS) is pegged at $4.87, indicating significant growth from the prior-year quarter’s reported figure.
Factors at Play
In the last reported quarter, Quidel’s Molecular Diagnostic Solutions delivered robust results. This momentum is likely to have continued in the to-be reported quarter as well. Further, higher sales of COVID-19 products are expected to have boosted growth in the to-be-reported quarter.
The company is likely to have witnessed an uptick in rapid immunoassay revenues in the fiscal first quarter on higher sales derived from the Sofia platform. Progress of this platform is expected to have been aided by an increase in Sofia SARS Antigen and Sofia Combo ABC product sales.
However, Quidel witnessed a decline in its specialized diagnostic solutions revenues in the last reported quarter. This downside was due to weak respiratory products in the company’s Cell Culture business, a trend that most likely continued in the fiscal first quarter too.
Also, Quidel witnessed softness in its overall Influenza revenues in the fourth quarter of fiscal 2020 due to a very low prevalence of Influenza in the period, a trend that most likely persisted in the first quarter of fiscal 2021 as well.
Nonetheless, overall molecular growth of the Lyra product category is expected to have contributed to the to-be-reported quarter’s top line, possibly led by an uptick in Solana SARS revenues.
In the to-be reported quarter, the company’s Cardiometabolic Immunoassay business is expected to have been driven by strength in the Triage business and the Beckman BNP business.
Advancement of the COVID-diagnostic product pipeline, especially with the Sofia Serology assay, is expected to have boosted the company’s performance in the fiscal first quarter. The FDA EUA approvals to market Solana SARS and QuickVue SARS Antigen is also expected to have driven growth in the to-be reported quarter.
Quidel Corporation Price and EPS Surprise
Quidel Corporation price-eps-surprise | Quidel Corporation Quote
Quidel has been evolving within its R&D and instrument systems development teams for a while now. This, in turn, is expected to reflect on its results for the fiscal first quarter. Moreover, solid momentum of the Savanna cross-functional product development team might have enhanced the company’s to-be-reported quarter’s performance.
In recent times, Sofia Q, formerly named Sniffles, which is the company’s next-generation Sofia platform, is steadily gaining traction. This is also likely to have bumped up the top line in the to-be-reported quarter.
Additionally, the company is expected to have consistently benefited from newer products like Sofia Lyme, TriageTrue, High Sense, Troponin assay, Triage PLGF and the new Sofia GI suite in the quarter as well.
What Our Quantitative Model Suggests
Our proven model does not predict an earnings beat for Quidel this time around. The combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the chances of an earnings beat. But that is not the case here as you will see.
Earnings ESP: Quidel has an Earnings ESP of -2.47%. You can uncover the best stocks to buy or sell before they're reported with our Earnings ESP Filter.
Zacks Rank: Quidel carries a Zacks Rank #5 (Strong Sell).
Zacks Rank and Key Picks
Here are some medical stocks worth considering as these have the right combination of elements to beat on earnings this reporting cycle.
AmerisourceBergen has an Earnings ESP of +0.23% and a Zacks Rank of 3, currently. You can see the complete list of today’s Zacks #1 Rank stocks here.
DENTSPLY SIRONA (XRAY - Free Report) has an Earnings ESP of +11.36% and is a Zacks #2 Ranked stock, presently.
Cerner Corporation has an Earnings ESP of +0.37% and a Zacks Rank of 3 at present.
More Stock News: This Is Bigger than the iPhone!
It could become the mother of all technological revolutions. Apple sold a mere 1 billion iPhones in 10 years but a new breakthrough is expected to generate more than 77 billion devices by 2025, creating a $1.3 trillion market.
Zacks has just released a Special Report that spotlights this fast-emerging phenomenon and 4 tickers for taking advantage of it. If you don't buy now, you may kick yourself in 2022.
Click here for the 4 trades >>